Columbia University’s Department of Medicine invites applications for a research position in the rank of Postdoctoral Research Fellow at The Columbia University Medical Center in the Division of Molecular Medicine (Alan Tall, Director). The position includes both laboratory and translational research.
The Tall laboratory is conducting research on the pathogenesis of metabolic diseases including atherosclerosis and fatty liver. A major goal of research is to use information derived from human genetic studies to identify novel genes and pathways involved in disease pathogenesis. This has led to the discovery that mutations in genes that cause hematological malignancies also promote atherosclerosis in mouse models and in humans. As people age they commonly acquire such mutations: this increases their risk of developing hematological malignancies but also unexpectedly diabetes and atherosclerosis. We are conducting research to elucidate the underlying cellular and molecular mechanisms which include excessive proliferation of hematopoietic stem cells, increased myelopoiesis and platelet production, platelet activation and macrophage inflammatory processes including inflammasome activation. An overarching goal is to use mechanistic discoveries as a guide to new therapeutic approaches to treating human metabolic diseases.
1: Thomas DG et al. LXR Suppresses Inflammatory Gene Expression and
Neutrophil Migration through cis-Repression and Cholesterol Efflux. Cell Rep.
2: Wang W et al. Macrophage Inflammation, Erythrophagocytosis, and Accelerated
Atherosclerosis in Jak2 (V617F) Mice. Circ Res. 2018 123:e35-e47.
3: Westerterp M et alCholesterol Efflux Pathways Suppress Inflammasome Activation,
NETosis, and Atherogenesis. Circulation. 2018 138:898-912.
4: Tall AR, Levine RL. Cardiovascular disease: Commonality with cancer. Nature.
List of References
Writing Sample/Publication 1
Writing Sample/Publication 2
Contacts: Dr. Alan Tall
Ms. Lilian A. Oling